Getinge (PINK:GETI B) said yesterday it launched a new combined angiography system designed for hybrid operating rooms as a collaborative project with GE Healthcare (NYSE:GE).
The system combines Getinge’s Maquet brand Magnus OR table with GE’s Discovery IGS 730 angiography system to allow for an expanded range of surgical procedures and interventions.
“Hybrid ORs have become the standard of care at medical centers throughout the United States as these multidisciplinary and multipurpose rooms have been shown to lead to improved clinical outcomes for cardiothoracic and other patients. With the U.S. launch of this new integrated solution that combines our MAGNUS OR table system, the centerpiece of a Hybrid OR, with GE’s angiography system, hospitals across the country will be able to provide the best care for their patients who require a variety of multidisciplinary surgical interventions,” Getinge surgical workflows veep of marketing for the Americas Mark Rider said in a press release.
Getinge’s Magnus OR table is designed with a “floating” function to allow for quick movements during catheter-based interventions, and can use interchangeable table tops for multiple clinical applications, the comapny said.
The Discovery IGS 730 angiography system is designed with a laser-guided mobile gantry to allow for better positioning in the OR, as well as allowing for high-quality 2D imagery and cone-beam CT HD and multimodality 3D fusion imaging.
In July, Getinge said it won expanded FDA clearance for its Sterizone VP4 sterilizer, now cleared to sterilize colonoscopes, gastroscopes and other multi-channel flexible endoscopes of up to 4 channels and 3.5 meters in length.
The Swedish medical device firm touted the win, saying that regulatory authorities are becoming more scrutinous of medical device reprocessing, particularly for colonoscopes and other complex minimally invasive surgical devices.
The post Getinge, GE Healthcare launch ‘hybrid OR’ flexible angiography combo appeared first on MassDevice.
from MassDevice http://ift.tt/2bmzZLa
Cap comentari:
Publica un comentari a l'entrada